Rapport Therapeutics, Inc. (RAPP)
41.95
+0.56
(+1.35%)
USD |
NASDAQ |
Sep 17, 16:00
41.92
-0.03
(-0.08%)
After-Hours: 20:00
Rapport Therapeutics Debt to Equity Ratio : 0.0239 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0239 |
| March 31, 2026 | 0.0229 |
| December 31, 2025 | 0.0237 |
| September 30, 2025 | 0.0232 |
| June 30, 2025 | 0.045 |
| March 31, 2025 | 0.0274 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.0048 |
| September 30, 2024 | 0.0051 |
| June 30, 2024 | 0.0054 |
| March 31, 2024 | 0.0102 |
| December 31, 2023 | 0.0152 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 458.98M |
| Total Liabilities (Quarterly) | 36.06M |
| Shareholders Equity (Quarterly) | 422.93M |
| Current Ratio | 15.72 |
| Net Debt Paydown Yield | -0.02% |